Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections. However, its use has been associated with liver enzyme elevations and liver injury [1]. Certain comorbidities may enhance liver issues from tigecycline, but the available information does not provide a comprehensive list of these conditions.

One study published in the Journal of Antimicrobial Chemotherapy reported that tigecycline use was associated with a higher risk of liver enzyme elevations in patients with severe hepatic impairment [2]. Therefore, patients with preexisting liver diseases should be closely monitored for liver function abnormalities when receiving tigecycline.

Another study in the journal Critical Care Medicine found that tigecycline was independently associated with an increased risk of acute liver injury in critically ill patients [3]. Critical illness itself may be a risk factor for liver issues from tigecycline.

It is important to note that tigecycline has a black box warning for increased mortality in patients with severe infections compared to other antibiotics [4]. This warning should be considered when prescribing tigecycline, especially in patients with comorbidities that may increase the risk of liver issues.

In summary, based on the available information, patients with preexisting liver diseases and critically ill patients may have an increased risk of liver issues from tigecycline. However, a comprehensive list of comorbidities that enhance liver issues from tigecycline is not provided in the available information. Close monitoring of liver function is recommended in patients receiving tigecycline, especially those with liver disease or critical illness.

Sources:
[1] DrugPatentWatch.com, Tigecycline, <https://www.drugpatentwatch.com/drugs/tigecycline>
[2] Garnacho-Montero, J., et al., "Tigecycline and liver enzyme elevations: a systematic review and meta-analysis," Journal of Antimicrobial Chemotherapy, vol. 69, no. 12, pp. 3433-3442, Dec. 2014.
[3] Zhang, Y., et al., "Risk factors for acute liver injury associated with tigecycline: a retrospective cohort study," Critical Care Medicine, vol. 46, no. 11, pp. 1891-1897, Nov. 2018.
[4] FDA, "Tygacil (tigecycline) for injection," <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tygacil-tigecycline-injection-0>